作为肺癌的潜在治疗候选者:新兴的临床前证据
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, Liaoning 110004, PR China.
概括
素是一种天然的黄类化合物,通过促进细胞死亡和抑制瘤生长,显示出对抗肺癌的前途. 本综述探讨了其作为一种新型治疗药物对抗肺癌的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 肺癌仍然是全球癌症死亡的主要原因之一.
- 现有的肺癌治疗方法存在重大局限性.
- 对于抗击肺癌进展的新型治疗药物有着至关重要的需求.
研究的目的:
- 审查最近关于黄素抗肺癌效应的研究结果.
- 为了探索黄素对肺癌的作用机制.
- 为开发基于黄素的新型抗肺癌药物提供见解.
主要方法:
- 在SCOPUS,谷歌学者,PubMed和Web of Science数据库中进行全面的文献搜索.
- 专注于1995年1月至2024年1月期间发表的研究.
- 使用的关键词:"luteolin"和"肺癌".
主要成果:
- 氨酸表现出对肺癌的多种治疗机制.
- 这些包括促进亡,抑制扩散,入侵和转移.
- 素还调节免疫反应,可以作为辅助疗法.
结论:
- 氨酸显示出作为一种抗肺癌剂的显著潜力.
- 它的多方面的机制为药物开发提供了新的途径.
- 进一步研究素可能会导致改善肺癌治疗方法.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K